Osmotica Pharmaceutical Announces the Appointment of Praveen Tyle, PhD as Executive Vice President and Chief Scientific Officer

Osmotica Pharmaceutical Announces the Appointment of Praveen Tyle, PhD as Executive Vice President and Chief Scientific Officer

10/15/2012 10:17:24 AM

WILMINGTON, N.C.--Osmotica Pharmaceutical Corp. today announced the appointment of Dr. Praveen Tyle as Executive Vice President and Chief Scientific Officer. He also serves as the Managing Director of Osmotica's Marietta, Georgia site. Forrest Waldon, CEO of Osmotica Pharmaceutical stated, "We are pleased to announce that Praveen Tyle has joined Osmotica as Chief Science Officer and Executive Vice President. Praveen is a proven industry veteran with an impressive record of moving pharmaceutical pipelines to commercial success."

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.